Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Healthtrust
QuintilesIMS
Merck
McKinsey
Cerilliant
Baxter
Express Scripts
Queensland Health
Teva

Generated: February 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,618,913

« Back to Dashboard

Summary for Patent: 5,618,913
Title: Insulin analogues
Abstract:Novel rapid-acting human insulin analogues are provided having less tendency to self-association into dimers, tetramers, hexamers, or polymers. The novel human insulin analogues are formed by substituting one or more of the amino acid residues of human insulin with naturally occuring amino acid residues. The amino acid residue substitutions are preferably more hydrophilic than the natural amino acid residue at the respective position in the molecule. Furthermore, the insulin analogues have the same charge or a greater negative charge at neutral pH than that of human insulin. Preferred amino acid substitutions are Asp, Glu, Ser, Thr, His, and Ile, and more preferred substitutions are Asp and Glu. The novel insulin analogues can be used for the preparation of rapid-acting insulin solutions.
Inventor(s): Brange; Jens J. V. (Klampenborg, DK), Norris; Kjeld (Hellerup, DK), Hansen; Mogens T. (Lynge, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:06/901,821
Patent Claim Types:
see list of patent claims
Compound; Formulation;

Drugs Protected by US Patent 5,618,913

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,618,913

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark3956/85Aug 30, 1985
Denmark4677/85Oct 14, 1985

International Patents Family Members for US Patent 5,618,913

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 241801 ➤ Try a Free Trial
Austria 113061 ➤ Try a Free Trial
Australia 593274 ➤ Try a Free Trial
Australia 6206686 ➤ Try a Free Trial
Canada 1306212 ➤ Try a Free Trial
China 1029977 ➤ Try a Free Trial
China 86106574 ➤ Try a Free Trial
Czechoslovakia 275613 ➤ Try a Free Trial
Czechoslovakia 8606310 ➤ Try a Free Trial
Germany 10075008 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
US Army
Johnson and Johnson
Express Scripts
Cipla
McKinsey
Deloitte
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot